J&J begins phase 3 ENSEMBLE Covid-19 vaccine trial for JNJ-78436735

pharmanewsdaily- September 23, 2020 0

ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), ... Read More

Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J

pharmanewsdaily- August 20, 2020 0

J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech ... Read More

Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt

pharmanewsdaily- August 5, 2020 0

Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S ... Read More

Johnson & Johnson coronavirus vaccine targeted to be launched in early 2021

pharmanewsdaily- March 31, 2020 0

Johnson & Johnson said that it has selected a lead coronavirus vaccine candidate from constructs it has been working on since the start of this ... Read More

J&J takeover of Verb Surgical : J&J strikes deal with Verily for full ownership in robotic surgery company

pharmanewsdaily- December 21, 2019 0

J&J takeover of Verb Surgical : Johnson & Johnson (J&J) has agreed to take full ownership in US robotic surgery company Verb Surgical by acquiring ... Read More

Janssen to acquire skin disease drug candidate bermekimab from XBiotech

pharmanewsdaily- December 8, 2019 0

Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational ... Read More

Janssen bags Stelara FDA approval for ulcerative colitis treatment

pharmanewsdaily- October 22, 2019 0

Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug ... Read More

Janssen bags Xarelto FDA approval to prevent blood clots in acutely ill patients

pharmanewsdaily- October 18, 2019 0

Xarelto FDA approval : The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for Xarelto ... Read More

Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint

pharmanewsdaily- July 29, 2019 0

Ponesimod OPTIMUM trial results :  Johnson & Johnson's Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to ... Read More

Guselkumab meets primary endpoints in phase 3 psoriatic arthritis program

pharmanewsdaily- June 15, 2019 0

Johnson & Johnson’s Janssen Pharmaceutical said that its IL-23 p19 inhibitor TREMFYA (guselkumab) met the primary endpoints of American College of Rheumatology 20% improvement (ACR20) ... Read More